Skip to main content
Ivan Maillard, MD, Oncology, Philadelphia, PA

IvanPatrickMaillardMDPhD

Oncology Philadelphia, PA

Hematologic Oncology

Professor of Medicine and Vice-Chief for Research, Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine

Dr. Maillard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Maillard's full profile

Already have an account?

  • Office

    3400 Spruce St
    Philadelphia, PA 19104
    Phone+1 215-615-0063
    Fax+1 215-349-8144

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2001 - 2005
  • University of Lausanne Faculty of Medicine
    University of Lausanne Faculty of MedicineClass of 1993

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2001 - 2024
  • MI State Medical License
    MI State Medical License 2007 - 2020
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

Journal Articles

  • Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers  
    Matthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine
  • The FOSSIL Study: FLAG or Standard 7+3 Induction Therapy in Secondary Acute Myeloid Leukemia  
    Dale L Bixby, Ivan P Maillard, Moshe Talpaz, Leukemia Research
  • Notch Signaling Mediated by Delta-like1/4 Ligands Controls the Pathogenesis of Chronic Graft-Versus-Host Disease in Mice  
    Ivan Maillard, Eric T Perkey, Maria A Pletneva, Stefanie Sarantopoulos, Bruce R Blazar, Vedran Radojcic, Blood
  • Join now to see all

Abstracts/Posters

  • Dll1 and Dll4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the O...
    Ivan Maillard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    Ivan Maillard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • SETDB1 Mediated H3K9 Methylation Suppresses MLL-Fusion Target Expression and Leukemic Transformation
    Ivan Maillard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Stromal Cell Immune Regulation in the Microenvironment 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • The PAF1c Subunit Cdc73 Is Essential for Hematopoiesis and Displays Differential Gene Regulation in MLL-AF9 Driven Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Pharmacologic Blockade of Notch/Delta-like Ligand 4 Signaling Protects from Gastrointestinal Acute Graft-Versus-Host Disease in Non-Human Primates 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Authored Content

  • The FOSSIL Study: FLAG or Standard 7+3 Induction Therapy in Secondary Acute Myeloid LeukemiaJune 2018

Press Mentions

  • Genome Toxicity and Impaired Stem Cell Function After Conditional Activation of CreERT2 in the Intestine
    Genome Toxicity and Impaired Stem Cell Function After Conditional Activation of CreERT2 in the IntestineNovember 15th, 2018
  • Antibody Prevents Gastrointestinal GVHD Without Broad Immunosuppression
    Antibody Prevents Gastrointestinal GVHD Without Broad ImmunosuppressionJuly 1st, 2023
  • Three-Drug Regimen Improves Protection Against GVHD After Stem Cell Transplant
    Three-Drug Regimen Improves Protection Against GVHD After Stem Cell TransplantJuly 18th, 2023
  • Join now to see all

Professional Memberships

Other Languages

  • French, German, Portuguese